369 related articles for article (PubMed ID: 37112897)
1. Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines.
Wang J; Huang L; Guo N; Yao YP; Zhang C; Xu R; Jiao YM; Li YQ; Song YR; Wang FS; Fan X
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112897
[TBL] [Abstract][Full Text] [Related]
2. Pediatric population (aged 3-11 years) received primary inactivated SARS-CoV-2 vaccination prior to infection exhibiting robust humoral immune response following infected with Omicron variant: a study conducted in Beijing.
Li J; Li J; Dai S; Dang L; Wang L; Cao L; Chen X; Wang Y; Ge M; Liu W; Song Q; Xu W; Ma L
Front Immunol; 2023; 14():1269665. PubMed ID: 37828994
[TBL] [Abstract][Full Text] [Related]
3. Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals.
Muena NA; García-Salum T; Pardo-Roa C; Avendaño MJ; Serrano EF; Levican J; Almonacid LI; Valenzuela G; Poblete E; Strohmeier S; Salinas E; Muñoz A; Haslwanter D; Dieterle ME; Jangra RK; Chandran K; González C; Riquelme A; Krammer F; Tischler ND; Medina RA
EBioMedicine; 2022 Apr; 78():103972. PubMed ID: 35366624
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
[TBL] [Abstract][Full Text] [Related]
5. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of SARS-CoV-2 neutralizing antibodies in Omicron breakthrough cases with inactivated vaccination: Role in inferring the history and duration of infection.
Simayi A; Li C; Chen C; Wang Y; Dong C; Tian H; Kong X; Zhou L; Peng J; Zhang S; Zhu F; Hu J; Xu K; Jin H; Fan H; Bao C; Zhu L
Front Immunol; 2023; 14():1083523. PubMed ID: 36761738
[TBL] [Abstract][Full Text] [Related]
7. A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort.
Tao Y; Ma M; Hu F; Li M; Geng Y; Wan Y; Mao M; Chen L; Shen Y; Zhu L; Shen H; Chen Y
BMC Immunol; 2022 Nov; 23(1):57. PubMed ID: 36384440
[TBL] [Abstract][Full Text] [Related]
8. Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum.
Liang D; Zhang G; Huang M; Wang L; Hong W; Li A; Liang Y; Wang T; Lu J; Ou M; Ren Z; Lu H; Zheng R; Cai X; Pan X; Xia J; Ke C
Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558864
[TBL] [Abstract][Full Text] [Related]
9. Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
Muñoz-Alía MÁ; Nace RA; Balakrishnan B; Zhang L; Packiriswamy N; Singh G; Warang P; Mena I; Narjari R; Vandergaast R; Peng K-W; García-Sastre A; Schotsaert M; Russell SJ
mBio; 2024 Feb; 15(2):e0292823. PubMed ID: 38193729
[TBL] [Abstract][Full Text] [Related]
10. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
[TBL] [Abstract][Full Text] [Related]
11. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
12. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China.
Zhang H; Hua Q; Nani Xu N; Zhang X; Chen B; Ma X; Hu J; Chen Z; Yu P; Lei H; Wang S; Ding L; Fu J; Liao Y; Yang J; Jiang J; Lv H
Elife; 2023 Mar; 12():. PubMed ID: 36928099
[TBL] [Abstract][Full Text] [Related]
14. Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection.
Zhou Y; Chen Z; He Y; Peng X; Chang Y; Tan A; Li H; Cai D; Hu P; Chen M; Peng M; Xu H; Ren H
Front Cell Infect Microbiol; 2023; 13():1201101. PubMed ID: 37457966
[TBL] [Abstract][Full Text] [Related]
15. Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort study.
Jia M; Wang X; Gong W; Zhong J; Leng Z; Ren L; Feng L; Guo L; Gao L; Liang X; Chen E; Tang W; Huang Q; Zhang Q; Jiang G; Zhao S; Liu Z; Feng Y; Qi L; Ma L; Huang T; Yue Y; Wang J; Jiang B; Xu L; Wang J; Yang W; Wang C
J Med Virol; 2022 Dec; 94(12):5746-5757. PubMed ID: 35941840
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China.
Yan LN; Zhao ZX; Wang ZD; Xiao X; Liu PP; Zhang WK; Gu XL; Li B; Yu LP; Yu XJ
Expert Rev Vaccines; 2022 Oct; 21(10):1465-1473. PubMed ID: 35861138
[TBL] [Abstract][Full Text] [Related]
17. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
18. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
19. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
[TBL] [Abstract][Full Text] [Related]
20. Sequentially immune-induced antibodies could cross-neutralize SARS-CoV-2 variants.
Lv Q; Zhou S; Qi F; Zhang Y; Li F; Liu M; Bao L
Animal Model Exp Med; 2022 Feb; 5(1):89-93. PubMed ID: 35213787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
